The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

The investigational BTK inhibitor zanubrutinib (BGB-3111) has received a breakthrough therapy designation from the FDA for the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 prior therapy, BeiGene, the company manufacturing the agent, has announced.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.